The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc. (NYSE:MRK) announced that the FDA approved both KEYTRUDA and KEYTRUDA QLEX each in combination with Gilead’s Trodelvy as a first-line treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 at a Combined Positive Score of 10 or higher. KEYTRUDA is the brand name for pembrolizumab, which is given intravenously, and KEYTRUDA QLEX is the brand name for a mixture of pembrolizumab and berahyaluronidase alfa-pmph, and is given as a subcutaneous injection.

The FDA Just Approved a KEYTRUDA Combination That Could Become the Standard First-Line Treatment for Aggressive Breast Cancer

Pressmaster/Shutterstock.com

Merck said the approvals are based on the Phase 3 KEYNOTE-D19/ASCENT-04 trial. It added that because TNBC advances rapidly, a large proportion of patients never make it to a second line of therapy, meaning the first treatment choice is often the only real opportunity to meaningfully extend life. Merck noted that these are the first approvals of a PD-1 inhibitor combined with a Trop-2-directed antibody-drug conjugate in advanced TNBC. The treatment replaces a chemotherapy backbone with a targeted-plus-immune approach.

Merck & Co., Inc. (NYSE:MRK) is a pharmaceutical company. It discovers, develops, manufactures, and markets prescription medicines, vaccines, and animal health products. Its portfolio includes KEYTRUDA and Gardasil, a vaccine for human papillomavirus.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy Now for Good Returns and 10 Best Growth Stocks to Buy According to Billionaire Dan Loeb.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1